(q) Neither the issuance and sale of the securities, nor the execution of other transactions contemplated, nor the compliance with the conditions provided for in them are in contradiction with a violation or violation or imposition of a pledge, royalty or charge of ownership or assets of the company or any of its subsidiaries, in accordance with (i) of the Charter or the statutes of the Company or its subsidiaries. (ii) the terms of any establishment, contract, contract, lease, mortgage, loyalty deed, credit contract, loan contract or other agreement, obligation, condition, agreement or one of its subsidiaries whose company or one of its subsidiaries is subject to partisan or related, or (iii) a law, law, rule, regulation , a judgment, injunction or decree that applies to the company or one of its subsidiaries in a court. , the regulator, the management authority, the government authority, the arbitrator or any other authority that is responsible for the company or one of its subsidiaries or any of its real estate assets, except in the case of clauses (ii) and (iii) as it is reasonable not to expect a significant adverse effect. (d) On or before the date of the interim prospectus, the selling shareholder executed an agreement essentially in the form of Schedule A and delivered it to the insurers. 11. Representations and compensation for survival. The agreements, insurance, guarantees, allowances and other statements of the company or its senior executives, the selling shareholder and the follow-up of this agreement remain fully in force and act independently of investigations conducted by or on behalf of an insurer, the selling shareholder or the company or one of the senior executives. , directors, employees, representatives, related entities or supervisors covered by Section 8 of this Directive and will survive the delivery and payment of the securities. The provisions of Sections 7 and 8 of this agreement also apply after the termination or termination of this contract. June 25, 2020 Translate Bio, Inc.
(the company) with Goldman Sachs and Co. LLC, SVB Leerink LLC and Evercore Group L.L.C. as representatives of the Underwriters (the Underwriters) and a shareholder of the company (shareholder of the right to sell) in respect of a signed public offer (the offer) of 5,681,819 shares (shares) of the company (the shareholder of the company) , on a value of $0.001 per share (common share) , offered by the Company, and 6,824,992 common shares offered by the stock of selling shares.